Mobilization of peripheral blood stem cells in children using G-CSF after carboplatin containing myelosuppressive chemotherapy

A novel intensive induction therapy for high‐risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support

“…The number of CD34 + cells collected was monitored and declined with each subsequent cycle again indicating increasing cumulative bone marrow toxicity of the regimen although PBSC collection was successfully completed in a median of 1 day (mean of 1.2, 1.3, and 1.3 days for collection 1, 2, and 3, respectively) following all three cycles. CD 34 + mobilization has subsequently been reported to be lower after carboplatin containing chemotherapy regimens 46.…”

Delayed short‐term administration of granulocyte colony‐stimulating factor is a good mobilization strategy for harvesting autologous peripheral blood stem cells in pediatric patients with solid tumors

“…In particular, it was difficult to use predictive factors such as serum lactate dehydrogenase levels because these are often high in pediatric patients. Although a negative correlation has been reported between the cumulative dose of carboplatin and the quality of PBSCs in pediatric patients with solid tumors , no significant differences were observed in the effects of prior chemotherapy regimens including carboplatin/cisplatin between the ST and LT groups (Table ). In addition, although the type of G‐CSF to be administered was determined by the attending physicians, the ST and LT groups received similar types of G‐CSF (Table ).…”